PMCID: PMC8138308 Morlino S, Micale L, Ritelli M, Rohrbach M, Zoppi N, Vandersteen A, Mackay S, Agolini E, Cocciadiferro D, Sasaki E, Madeo A, Ferraris A, Reardon W, Di Rocco M, Novelli A, Grammatico P, Malfait F, Mazza T, Hakim A, Giunta C, Colombi M, Castori M
ESPE Year Book
There are currently no FDA-approved GLP-1 receptor agonists that can be administered orally
Your genes can impact how you respond to a GLP-1 In a study published in Genome Medicine , researchers found that about 10 percent of people carry certain variants of what's known as the PAM gene, and those individuals had a weaker blood sugar response to GLP-1based drugs compared to non-carriers
The effect is usually indirect, caused by fatigue from caloric restriction, GI discomfort, or hormonal shifts from rapid weight loss